Page 1451 - Williams Hematology ( PDFDrive )

1426 Part X: Malignant Myeloid Diseases Chapter 88: Acute Myelogenous Leukemia 1427

676. Lowenberg B: Sense and nonsense of high-dose cytarabine for acute myeloid leuke- 704. Anasetti C, Logan BR, Lee SJ, et al: Peripheral-blood stem cells versus bone marrow
mia. Blood 121:26, 2013. from unrelated donors. N Engl J Med 367:1487, 2012.
677. Schaich M, Rollig C, Soucek S, et al: Cytarabine dose of 36 g/m compared with 12 g/m 2 705. Applebaum FR: Is there a best transplant conditioning regimen for acute myeloid
2
within first consolidation in acute myeloid leukemia: Results of patients enrolled onto leukemia? Leukemia 14:497, 2000.
the prospective randomized AML96 study. J Clin Oncol 29:2696, 2011. 706. Litzow MR, Perez WS, Klein JP, et al: Comparison of outcome following allogeneic
678. Graves T, Hooks MA: Drug-induced toxicities associated with high-dose cytosine ara- bone marrow transplantation with cyclophosphamide-total body irradiation ver-
binoside infusions. Pharmacotherapy 9:23, 1989. sus busulphan-cyclophosphamide conditioning regimens for acute myelogenous
679. Smith GA, Damon LE, Rugo HS, et al: High-dose cytarabine dose modification leukaemia in first remission. Br J Haematol 119:1115, 2002.
reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 707. Nagler A, Racha V, Labopin M, et al: Allogeneic hematopoietic stem cell transplan-
15:833, 1997. tation for acute myeloid leukemia in remission: Comparison of intravenous busulfan
680. Hewlett J, Kopecky KJ, Head D, et al: A prospective evaluation of the roles of alloge- plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning
neic marrow transplantation and low-dose monthly maintenance chemotherapy in regimen—A report from the acute leukemia working party of the European group for
the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology blood and marrow transplantation. J Clin Oncol 31:3549, 2013.
Group study. Leukemia 9:562, 1995. 708. Copelan EA, Hamilton BK, Avalos B, et al: Better leukemia-free and overall survival
681. Laille E, Savona MR, Scott BL, et al: Pharmacokinetics of different formulations of oral in AML in first remission following cyclophosphamide in combination with busulfan
azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacoki- compared with TBI. Blood 122;3863, 2013.
netics in subjects with hematologic malignancies J Clin Pharmacol 54:630, 2014. 709. Tallman MS, Rowlings PA, Milone G, et al: Effect of postremission chemotherapy
682. Breems DA, Löwenberg B: Autologous stem cell transplantation in the treatment of before human leukocyte antigen-identical sibling transplantation for acute myelog-
adults with acute myeloid leukaemia. Br J Haematol 130:825, 2005. enous leukemia in first complete remission. Blood 96:1254, 2000.
683. Gorin NC: Autologous stem cell transplantation in acute myelocytic leukemia. Blood 710. Rowe JM: Is there a role for consolidation therapy pre-transplantation? Best Pract Res
92:1073, 1998. Clin Haematol 19:301, 2006.
684. Schiller G, Lee M, Miller T, et al: Transplantation of autologous peripheral blood pro- 711. Mehta J, Powles R, Treleaven J, et al: Long-term follow-up of patients undergoing
genitor cells procured after high-dose cytarabine-based consolidation chemotherapy allogeneic bone marrow transplantation for acute myeloid leukemia in first complete
for adults with acute myelogenous leukemia in first remission. Leukemia 11:1533, 1997. remission after cyclophosphamide-total body irradiation and cyclosporine. Bone
685. Gondo H, Harada M, Miyamoto T, et al: Autologous peripheral blood stem cell trans- Marrow Transplant 18:741, 1996.
plantation for acute myelogenous leukemia. Bone Marrow Transplant 20:821, 1997. 712. Robin M, Guardiola P, Dombret H, et al: Allogeneic bone marrow transplantation for
686. Meloni G, Vignetti M, Avvisati G, et al: BAVC regimen and autograft for acute mye- acute myeloblastic leukaemic in remission: Risk factors for long-term morbidity and
logenous leukemia in second complete remission. Bone Marrow Transplant 18:693, mortality. Bone Marrow Transplant 31:877, 2003.
1996. 713. Greinex HT, Nachbaur D, Krieger O, et al: Factors affecting long-term outcome after
687. Kusnierz-Glaz CR, Schlegel PG, Wong RM, et al: Influence of age on the outcome of allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia:
500 autologous bone marrow transplant procedures for hematologic malignancies. A retrospective study of 172 adult patients reported to the Austrian Stem Cell Trans-
J Clin Oncol 15:18, 1997. plant Registry. Br J Haematol 117:914, 2002.
688. Mehta J, Powles R, Singhal S, et al: Autologous bone marrow transplantation for acute 714. Mathews V, DiPersio JF: Stem cell transplantation in acute myelogenous leukemia in
myeloid leukemia in first remission: Identification of modifiable prognostic factors. first remission: What are the options? Curr Hematol Rep 3:235, 2004.
Bone Marrow Transplant 16:499, 1995. 715. Bornhäuser M, Illmer T, Schaich M, et al: Improved outcome after stem-cell trans-
689. Miller CB, Rowlings PA, Zhang MJ, et al: The effect of graft purging with 4-hydroper- plantation in FLT3/ITD-positive AML. Blood 109:2264, 2007.
oxycyclophosphamie in autologous bone marrow transplantation or acute myeloge- 716. DeZern AE, Sung A, Kim S, et al: Role of allogeneic transplantation for FLT3/ITD
nous leukemia. Exp Hematol 29:1336, 2001. actue myeloid leukemia: Outcomes from 133 consecutive newly diagnosed patients
690. Abdallah A, Egerer G, Weberf-Nordt RM, et al: Long-term outcome in acute myelog- from a single institution. Biol Blood Marrow Transplant 17:1404, 2011.
enous leukemia autografted with mafosfamide-purged marrow in a single institution: 717. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/SAKK donor
Adverse events and incidence of secondary myelodysplasia. Bone Marrow Transplant versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplan-
30:15, 2002. tation in first remission acute myeloid leukemia in young and middle-aged adults:
691. Bishop MR, Jackson JD, Tarantolo SR, et al: Ex vivo treatment of bone marrow with Benefits for whom? Blood 109:3658, 2007.
phosphorothioate oligonucleotide OL(l) p53 for autologous transplantation in acute 718. Appelbaum FR, Pearce SF: Hematopoietic cell transplantation in first complete remis-
myelogenous leukemia and myelodysplastic syndrome. J Hematother 6:441, 1997. sion versus early relapse. Best Pract Res Clin Haematol 19:333, 2006.
692. To LB, Haylock DN, Thorp D, et al: The optimization of collection of peripheral blood 719. Matthews DC, Appelbaum FR, Eary JF, et al: Development of a marrow transplant
stem cells for autotransplantation in acute myeloid leukaemia. Bone Marrow Trans- regimen for acute leukemia using targeted hematopoietic irradiation delivered by
plant 4:41, 1989. 131 I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body
693. Hogge DE, Ailles LE, Gerhard B: Cytokine responsiveness of primitive progenitors in irradiation. Blood 85:1122, 1995.
acute myelogenous leukemia. Leukemia 11:2220, 1997. 720. Zuckerman T, Rowe JM: Alternative donor transplantation in acute myeloid leuke-
694. Carella AM, Dejana A, Lerma E, et al: In vivo mobilization of karyotypically normal mia: Which source and when? Curr Opin Hematol 14:152, 2007.
peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related 721. Gragert L, Eapen M, Williams E, et al: HLA match likelihoods for hematopoietic
acute myelogenous leukaemia. Br J Haematol 95:127, 1996. stem-cell grafts in the U. S. registry. N Engl J Med 371:339, 2014.
695. Mehta J, Powles R, Horton C, et al: Factors affecting engraftment and hematopoi- 722. Mawad B, Gooley TA, Sandhu V, et al: Frequency of allogeneic hematopoietic cell
etic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant transplantation among patients with high- or intermediate-risk acute myeloid leuke-
18:319, 1996. mia in first complete remission. J Clin Oncol 31:3883, 2013.
696. Gorin NC, Labopin M, Blaise D, et al: Higher incidence of relapse with peripheral 723. Sasazuki T, Juji T, Morishima Y, et al: Effect of matching of class I HLA alleles on
blood rather than marrow as a source of stem cells in adults with acute myelocytic clinical outcome after transplantation of hematopoietic stem cells from an unrelated
leukemia autografted during the first remission. J Clin Oncol 27:3987, 2009. donor. Japan Marrow Donor Program. N Engl J Med 339:1177, 1998.
697. Voog E, Le QH, Philip I, et al: Autologous transplantation in acute myeloid leukemia: 724. Saber W, Opie S, Rizzo JD, et al: Outcomes after matched unrelated donor versus
Peripheral blood stem cell harvest after mobilization in steady state by granulocyte identical sibling hematopoietic cell transplantation in adults with acute myelogenous
colony-stimulating factor alone. Ann Hematol 80:584, 2001. leukemia. Blood 119: 3908, 2012.
698. Ganguly S, Singh J, Divine CL, et al: Is there a plateau in the survival curve after 725. Schlenk RF, Dohner K, Mack S, et al: Prospective evaluation of allogeneic hematopoi-
autologous transplantation in patients with intermediate and high-risk acute myeloid etic stem cell transplantation from matched related and matched unrelated donors
leukemia? A 20-year single institution experience. Leuk Res 31:1253, 2007. in younger adults with high-risk acute myeloid leukemia: German-Austrian trial
699. Chauncey TR: Autologous bone marrow transplantation improves disease-free sur- AMLHD98A. J Clin Oncol 28:4642, 2010.
vival but not overall survival in people with acute myeloid leukaemia. Cancer Treat 726. Ooi J, Iseki T, Takahashi S, et al: Unrelated cord blood transplantation for adult
Rev 30:483, 2004. patients with de novo acute myeloid leukemia. Blood 103:489, 2004.
700. Specchia G, Pastore D, Mestice A, et al: Early and long-term engraftment after autol- 727. Michel G, Rocha V, Chevret S, et al: Unrelated cord blood transplantation for child-
ogous peripheral stem cell transplantation in acute myeloid leukemia patients. Acta hood acute myeloid leukemia: A Eurocord Group Analysis. Blood 102:4290, 2003.
Haematol 116:229, 2006. 728. Haspel RL, Ballen KK: Double cord blood transplants: Filling a niche? Stem Cell Rev
701. Gupta V, Tallman MS, Weisdorf DJ: Allogeneic hematopoietic cell transplantation 2:81, 2006.
for adults with acute myeloid leukemia: Myths, controversies, and unknowns. Blood 729. Bacigalupo A, Ballen K, Rizzo D, et al: Defining the intensity of conditioning regi-
117:2307, 2011. mens: Working definitions. Biol Blood Marrow Transplant 15:1628, 2009.
702. Popplewell LL, Forman SJ: Is there an upper age limit for bone marrow transplanta- 730. Giralt S, Ballen K, Rizzo D, et al: Reduced-intensity conditioning regimen workshop:
tion? Bone Marrow Transplant 29:277, 2002. Defining the dose spectrum. Report of a workshop convened by the center for inter-
703. Lemoli RM, Bandini G, Leopardi G, et al: Allogeneic peripheral blood stem cell national blood and marrow transplant research. Biol Blood Marrow Transplant 15:367,
transplantation in patients with early-phase hematologic malignancy: A retrospective 2009.
comparison of short-term outcome with bone marrow transplantation. Haematologica 731. Storb R: Mixed allogeneic chimerism and graft-versus-leukemia effects in acute mye-
83:48, 1998. loid leukemia. Leukemia 16:753, 2002.

Kaushansky_chapter 88_p1373-1436.indd 1426 9/21/15 11:02 AM